Obesity Clinical Trial Monitor — GLP-1, Incretin & Weight Loss Pipeline Alerts 2026

The obesity clinical trial landscape in 2026

No therapeutic area has moved faster in the past three years than obesity pharmacotherapy. The approval of semaglutide (Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) as dedicated obesity treatments validated the incretin class at massive commercial scale and unleashed the largest competitive response in metabolic disease history. As of 2026, obesity is now one of the most crowded Phase 2 pipelines in all of biopharma, with dozens of programs advancing across GLP-1, GIP/GLP-1, triple agonist (GIP/GLP-1/GCG), amylin analog, and non-incretin mechanisms.

The 83 active trials in our database span both the incretin class and earlier-stage mechanistic programs. The most watched programs include Novo Nordisk's cagrilintide (amylin analog) in combination with semaglutide (CagriSema, Phase 3), Eli Lilly's retatrutide (GIP/GLP-1/GCG triple agonist, Phase 3), AstraZeneca/Eccogene's mazdutide (GCG/GLP-1, Phase 3 in Asia), and a wave of oral GLP-1 candidates including orforglipron (Lilly), danuglipron (Pfizer, development paused), and CT-996 (Lilly). BD desks need to see every new program registration the day it happens.

Beyond the incretin class, next-generation mechanisms are entering Phase 1 and Phase 2: GDF15 analogs, GPR75 antagonists, MC4R agonists, and GIPR antibodies (as both agonists and antagonists — a genuinely contested mechanistic question). The competitive landscape is changing faster than any manual monitoring process can track.

• GLP-1 receptor agonists — semaglutide, liraglutide, and next-generation subcutaneous/oral formulations
• GIP/GLP-1 dual agonists — tirzepatide and pipeline follow-ons
• GIP/GLP-1/GCG triple agonists — retatrutide, mazdutide, HM15211 (Hanmi)
• Amylin analogs and combinations — cagrilintide, pramlintide long-acting variants
• Oral small-molecule GLP-1 agonists — orforglipron, CT-996, lotiglipron
• Non-incretin mechanisms — GDF15, MC4R agonists, GPR75, mitochondrial uncouplers

What we monitor for obesity

Our system pulls from the ClinicalTrials.gov API every day. For an obesity watch profile, you can configure alerts for:

• Keywords: "obesity," "overweight," "BMI," "weight loss," "GLP-1," "tirzepatide," "semaglutide," "retatrutide," "orforglipron," "amylin," "incretin," "adiposity"
• Phase filters: Phase 1 (new mechanisms), Phase 2 (dose-finding), Phase 3 (pivotal outcome trials)
• Sponsor type: large pharma, mid-size biotech, academic/NIH-funded mechanistic studies
• Study status: not yet recruiting (earliest signal), recruiting, active not recruiting
• Comorbidity scope: obesity alone vs. obesity + T2D, obesity + NASH/MASH, obesity + cardiovascular

The oral GLP-1 race — the most-watched sub-competition in obesity pharma

The next major commercial battleground in obesity pharmacotherapy is oral bioavailability. Semaglutide oral (Rybelsus) exists for T2D but requires fasting and a very small water volume, limiting uptake. Eli Lilly's orforglipron is a non-peptide small molecule GLP-1 agonist completing Phase 3 — if approved, it would be the first truly convenient oral obesity drug and could expand the treatable population significantly. Pfizer's danuglipron showed Phase 2 efficacy but was paused due to tolerability; Pfizer has continued with a once-daily formulation. Lilly's CT-996 is in Phase 1.

For BD and CI teams, every new Phase 1 registration in oral GLP-1 or non-peptide incretin mechanisms is a signal worth tracking. Small companies with novel formulation technologies or differentiated peptide chemistry are likely targets for partnership or acquisition before Phase 3. DataLookout will surface those registrations on the morning they appear.

Patient advocacy organizations and health system strategy teams are also tracking this space closely. If oral GLP-1 agents achieve 15–20% weight loss with a once-daily pill, the public health implications — and the pipeline of obesity-related complication trials — will expand dramatically.

Who uses obesity trial monitoring

• Pharma and biotech BD teams — tracking new entrants in GLP-1, oral incretin, and non-incretin obesity mechanisms before they advance to partnering-stage Phase 2
• Metabolic disease and healthcare investors — monitoring Phase 3 enrollment progress and new catalyst-generating trials across the incretin landscape
• Obesity-focused CROs — identifying new sponsor relationships and site opportunities in the rapidly expanding Phase 2/3 obesity trial pipeline
• Patient advocacy groups and health policy organizations — tracking access to new weight-loss therapies and the breadth of Phase 3 populations being studied
• Medical affairs and market access teams — watching competitor Phase 3 programs for label differences, head-to-head designs, and real-world evidence studies

How DataLookout works

We run a direct API connection to ClinicalTrials.gov every morning, collecting all new and updated trials. Our matching engine compares each trial against your profile — condition keywords, drug targets, phase, sponsor type, and study status. Only relevant trials reach your inbox.

Your daily digest includes: trial title, phase, sponsor, current status, enrollment target, primary endpoint, and a direct link to the ClinicalTrials.gov record. No noise, no duplicate alerts.

Pricing

Free — $0 forever: 1 disease tracker, weekly digest, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, all phase and sponsor filters. Best for individual analysts.

Pro — $149/month: Unlimited profiles, daily digest, priority support. Best for BD and CI teams.